UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study

Scientific reports, 2021-04, Vol.11 (1), p.7975-7975, Article 7975

2021

Volltextzugriff (PDF)

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood, 2022-12, Vol.140 (22), p.2407-2411

2022

Volltextzugriff (PDF)

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia

International journal of molecular sciences, 2024-06, Vol.25 (11), p.5771

2024

Volltextzugriff (PDF)

Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma

Bone marrow transplantation (Basingstoke), 2020-07, Vol.55 (7), p.1460-1463

2020

Volltextzugriff (PDF)

Tattoo Pigment-Induced Granulomatous Lymphadenopathy Mimicking Lymphoma

Annals of internal medicine, 2017-12, Vol.167 (11), p.830

2017

Volltextzugriff (PDF)

Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice‐site CBL variant alongside a novel constitutional CSF3R variant

EJHaem, 2024-04, Vol.5 (2), p.397-402

2024

Volltextzugriff (PDF)

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia

Haematologica (Roma), 2018-05, Vol.103 (5), p.e223

2018

Volltextzugriff (PDF)

S134: FLAG‐IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

HemaSphere, 2023-08, Vol.7 (S3), p.e252478c-n/a

2023

Volltextzugriff (PDF)

P484: GEMTUZUMAB‐BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

HemaSphere, 2023-08, Vol.7 (S3), p.e13145db-n/a

2023

Volltextzugriff (PDF)

Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

The Lancet. Haematology, 2023-07, Vol.10 (7), p.e478-e479

2023

Volltextzugriff (PDF)

Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients

Leukemia & lymphoma, 2022-12, Vol.63 (14), p.3418-3425

2022

Volltextzugriff (PDF)

Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes

Current opinion in infectious diseases, 2021-12, Vol.34 (6), p.635

2021

Volltextzugriff (PDF)

Talaromyces marneffei and dysplastic neutrophils on blood smear in newly diagnosed HIV

Blood, 2018-01, Vol.131 (2), p.269-269

2018

Volltextzugriff (PDF)

Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies

Internal medicine journal, 2023-03, Vol.53 (3), p.323-329

2023

Volltextzugriff (PDF)

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood, 2024-05, Vol.143 (19), p.1931

2024

Volltextzugriff (PDF)

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Blood, 2022-11, Vol.140 (Supplement 1), p.3377-3378

2022

Volltextzugriff (PDF)

Allogeneic haematopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: A report from Australia and New Zealand Transplant and Cellular Therapies

Internal medicine journal, 2022-07

2022

Volltextzugriff (PDF)

Multiply relapsed mixed histiocytosis in an adult responding to clofarabine after failure of cladribine

Leukemia & lymphoma, 2020-01, Vol.61 (2), p.477-480

2020

Volltextzugriff (PDF)

High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.2364-2364

2021

Volltextzugriff (PDF)

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Blood, 2021-11, Vol.138 (Supplement 1), p.2929-2929

2021

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(57)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(29)
Hematology
(18)
Humans
(18)
Adult
(7)
Leukemia, Myeloid, Acute - Genetics
(7)
Mutation
(7)
Immunology
(6)
Transplantation
(6)
Female
(5)
Leukemia, Myeloid, Acute - Drug Therapy
(5)
Oncology
(5)
Aged
(4)
Infectious Diseases
(4)
Male
(4)
Middle Aged
(4)
Physical Sciences
(4)
Prognosis
(4)
Stem Cell Transplantation
(4)
Chemistry
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia

Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma

Tattoo Pigment-Induced Granulomatous Lymphadenopathy Mimicking Lymphoma

Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice‐site CBL variant alongside a novel constitutional CSF3R variant

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia

S134: FLAG‐IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

P484: GEMTUZUMAB‐BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients

Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes

Talaromyces marneffei and dysplastic neutrophils on blood smear in newly diagnosed HIV

Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: a report from Australia and New Zealand transplant and cellular therapies

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Allogeneic haematopoietic cell transplant services in Australia and New Zealand in the first year of the COVID‐19 pandemic: A report from Australia and New Zealand Transplant and Cellular Therapies

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Overlapping features of therapy-related and de novo NPM1-mutated AML

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

Multiply relapsed mixed histiocytosis in an adult responding to clofarabine after failure of cladribine

High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Suchergebnisse filtern